OREGOVOMAB for Advanced epithelial ovarian cancer | Fallopian tube cancer | Peritoneal carcinoma

Inclusion criteria

• {"criterion_text":"- Adults 18 years old or older\n- Adequate renal function: a. Creatinine ≤ 1.5 times ULN\n- ECOG Performance Status of 0 or 1\n- For women of childbearing potential, must be willing to avoid pregnancy by using a highly effective method of contraception from the first dose of study treatment to 6 months after last dose of study treatment. Adequate contraception is defined in Section 8.2.5. (Belgium and South Korea Only: Use of a highly effective method of contraception from 28 days before first dose).\n- Signed informed consent and authorization permitting release of personal health information.\n- Willingness and ability to complete patient quality of life questionnaires.\n- Subjects with newly diagnosed epithelial adenocarcinoma of ovarian, fallopian tube or peritoneal origin FIGO Stage III or IV disease.\n- Eligible histologic epithelial cell types: high grade serous adenocarcinoma, high grade endometrioid adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, or adenocarcinoma not otherwise specified (N.O.S.).\n- Completed debulking surgery (either primary debulking surgery or interval debulking surgery at the discretion of the investigator), as defined below: a. For subjects who undergo primary debulking surgery (Cohort 1 - Primary Surgery): i. Subject must receive initial dose of paclitaxel 175 mg/m2 given intravenously, and carboplatin AUC 6 IV every 3 weeks (21 days) for 6 cycles. Carboplatin total dose given as 5 consecutive daily pulse doses, for subjects who experiences significant grade 3 or higher emesis. Subsequent dose modifications will be instituted per protocol. Cycle 1 of chemotherapy ± oregovomab/placebo must be anticipated to occur within 6 weeks after primary debulking surgery, and ii. The primary debulking surgery is optimal, R1 or R0 (defined as R1, macroscopic less than 1 cm in diameter, or R0, microscopic or no evidence of tumor). Assessment of intra-abdominal optimal debulking will be determined at the time of the surgical procedure and not by postsurgical imaging (i.e., CT scan). Assessment of intra-abdominal optimal debulking will be determined at the time of the surgical procedure and not by post-surgical imaging (i.e., CT scan). b. For subjects who will undergo interval debulking surgery (IDS) (Cohort 2 – NACT+/Interval Surgery): i. Prior to IDS, subject must have received neoadjuvant treatment with 3cycles of paclitaxel and carboplatin a) paclitaxel must have been started at an initial dose of 175 mg/m2 given intravenously (IV) every 3 weeks (21 Days) ). If the subject experienced grade 3 or 4 adverse events with paclitaxel 175mg/m2, dose reduction to 135 mg/m2 is allowed for cycles 2 and/or 3. b) Carboplatin initial dose must have been an area under the curve (AUC) 5-6 IV approximately every 3 weeks (21 Days) ii. Once subjects are enrolled on the protocol, they must receive paclitaxel 175mg/m2 IV and carboplatin AUC 5-6 IV every 3 weeks starting cycle 4. Subsequent dose modifications will be instituted per protocol. Cycle 4 of chemotherapy ± oregovomab/placebo must be anticipated to occur within 6 weeks after interval debulking surgery, and iii. The interval debulking surgery is optimal, R1 or R0 (defined as R1, macroscopic less than 1 cm in diameter, or R0, microscopic or no evidence of tumor). Assessment of optimal debulking of intra-abdominal disease will be determined at the time of the surgical procedure and not by post-surgical imaging (i.e., CT scan).\n- Suitable venous access for the study-required procedures.\n- CA 125 levels: a) Cohort 1 – Primary Surgery: Preoperative serum CA-125 levels ≥ 50 U/mL, or b) Cohort 2 – NACT + Interval Surgery: serum CA-125 levels ≥ 50 U/mL prior to first neoadjuvant chemotherapy.\n- Adequate bone marrow function: a. Absolute neutrophil count (ANC) ≥ 1,500/μL b. Platelets ≥ 100,000/μL\n- Hemoglobin ≥ 8.0 g/dL (Note: Blood transfusion is permitted up to 48 hours before first dose of study treatment).\n- Adequate liver function: a. Bilirubin < 1.5 times upper limit of normal (ULN) b. Lactate Dehydrogenase (LDH), SGOT/AST and SGPT/ALT < 2.5 times ULN"}

Exclusion criteria

• {"criterion_text":"- BRCA1 or BRCA2 germline gene mutation test result with: a. Pathogenic, ambiguous or inconclusive result available within 28 days prior to starting study treatment. Subjects with BRCA1 or BRCA2 variants of uncertain significance can enroll onto the study as long as there is no intent to administer PARP inhibitors for front-line maintenance therapy, or b. Known BRCA1 and BRCA2 somatic mutations, if testing is performed\n- Recognized acquired, hereditary, or congenital immunodeficiency disease, including cellular immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia.\n- Clinically significant active infection(s) at the time of screening.\n- Any of the following conditions (on-study testing is not required unless it is required by a specific participating country): a. Known HIV-infected subjects unless on effective anti-retroviral therapy with an undetectable viral load within 6 months, or b. Known or suspected hepatitis B if active infection (subjects with chronic hepatitis B infection must have an undetectable HBV viral load on suppressive therapy, if indicated; positive surface antibody alone is not an exclusion), or c. Known or suspected hepatitis C infection which has not been treated and cured unless currently on treatment with an undetectable viral load).\n- Uncontrolled or life-threatening diseases compromising safety evaluation.\n- Diagnosed or treated for another malignancy within 5 years before the first dose, or previously diagnosed with another malignancy and have any evidence of residual disease, including ductal carcinoma in situ of the breast. Subjects with non-melanoma skin cancer, other carcinoma in situ if have undergone complete resection or cervix carcinoma in situ are not excluded if they have undergone complete resection. Synchronous endometrial and prior diagnosis of endometrial cancer within 5 years is not excluded if all of the following conditions are met: Stage IA, superficial myometrial invasion, without lymphovascular invasion, and not poorly differentiated subtypes including papillary serous, clear cell lesions.\n- Contraindications to the use of pressor agents.\n- Undergone more than one surgical debulking or have not recovered from surgery.\n- Anticipated treatment with any other anti-cancer medications, including bevacizumab, PARP inhibitors, or any investigational agent(s) during the study.\n- History or evidence upon physical examination of CNS disease, seizures not controlled with standard medical therapy, or any brain metastases.\n- Any of the following cardiovascular conditions: a. Acute myocardial infarction within 6 months before the first dose of study treatment. b. Current history of New York Heart Association (NYHA) Class III or IV heart failure (see Appendix H). c. Evidence of current uncontrolled cardiovascular conditions including cardiac arrhythmias, angina, pulmonary hypertension, or electrocardiographic clinically significant findings\n- Known Somatic Homologous Recombination Deficiency (HRD) who will receive PARP inhibitor front-line maintenance therapy. Subjects with somatic HRD are eligible as long as there is no intent to administer PARP inhibitor front-line maintenance therapy.\n- Unable to read or understand or unable to sign the necessary written consent before starting treatment.\n- May not receive any live, attenuated vaccine administered within 28 days (or 4 weeks) prior to enrolment, during the study, and for at least 90 days after the last dose of study treatment.\n- Subjects who receive Hyperthermic Intraperitoneal Chemotherapy (HIPEC), any other anti-cancer medications, including bevacizumab, PARP inhibitors, or any other investigational agent(s) with 3 cycles of paclitaxel and carboplatin neo-adjuvant treatment prior to IDS will be excluded.\n- Subjects with mucinous adenocarcinoma, carcinosarcoma, tumors with neuroendocrine features and low-grade adenocarcinoma.\n- Female subjects who are lactating and breastfeeding, orbreastfeeding or have a positive serum pregnancy test within 7 days prior to the first dose of study treatment (C1D1 for Cohort 1 or C4D1 for Cohort 2).\n- Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.\n- Active autoimmune disease, such as rheumatoid arthritis, SLE, ulcerative colitis, Crohn's Disease, MS, or ankylosing spondylitis requiring active disease modifying treatment.\n- Known allergy to murine proteins or hypersensitivity to any of the excipients of the oregovomab, paclitaxel, or carboplatin.\n- Chronically treated with immunosuppressive drugs such as cyclosporine, adrenocorticotropic hormone (ACTH), etc.\n- Chronic therapeutic corticosteroid use, defined as > 5 days of prednisone or equivalent, with the exception of inhalers or those on a pre-planned steroid taper. (Note: Premedication with corticosteroids per institutional standard of care is allowed.)"}

Primary endpoints

• {"endpoint_text":"- PFS, defined as date of randomization which occurs following surgery to the date of event defined as the first documented progression as per RECIST v1.1 as determined by the investigator or death due to any cause","definition_or_measurement_approach":"Progression-free survival (PFS) assessed from date of randomization after surgery to first documented progression per RECIST v1.1 by investigator assessment, or death from any cause. (Investigator assessment of scans according to RECIST v1.1)"}

Secondary endpoints

• {"endpoint_text":"- OS, defined as date of randomization to date of death due to any cause","definition_or_measurement_approach":"Overall survival (OS) measured from date of randomization to date of death from any cause."}
• {"endpoint_text":"- Incidence of adverse events (AEs) – including AEs, serious AEs (SAEs), deaths, and AEs leading to discontinuation of treatment, frequency/ severity of vital signs measurements, physical examination findings, and changes in clinical laboratory parameters (haematology, biochemistry, urinalysis)","definition_or_measurement_approach":"Safety and tolerability assessed by incidence and severity of AEs/SAEs, deaths, AEs leading to discontinuation, vital signs, physical exam findings, and clinical laboratory changes (haematology, biochemistry, urinalysis)."}
• {"endpoint_text":"- Change from baseline in the global health status/QOL scale score of the Functional Assessment of Cancer Therapy-Ovary (FACT-O TOI) and 3 additional questions from the NFOSI-18 in each treatment group.","definition_or_measurement_approach":"Health-related quality of life assessed by change from baseline in FACT-O Trial Outcome Index (TOI) score and 3 additional NFOSI-18 questions, compared between treatment groups."}

Czechia

Earliest CTIS Part Ii Submission Date

29-10-2024

Latest Decision Or Authorization Date

27-11-2024

Processing Time Days

29

Number Of Sites

5

Number Of Participants

26

Hungary

Earliest CTIS Part Ii Submission Date

29-10-2024

Latest Decision Or Authorization Date

20-11-2024

Processing Time Days

22

Number Of Sites

5

Number Of Participants

10

Spain

Earliest CTIS Part Ii Submission Date

29-10-2024

Latest Decision Or Authorization Date

20-11-2024

Processing Time Days

22

Number Of Sites

5

Number Of Participants

13

Belgium

Earliest CTIS Part Ii Submission Date

28-10-2024

Latest Decision Or Authorization Date

22-11-2024

Processing Time Days

25

Number Of Sites

3

Number Of Participants

6

Italy

Earliest CTIS Part Ii Submission Date

29-10-2024

Latest Decision Or Authorization Date

10-01-2025

Processing Time Days

74

Number Of Sites

2

Number Of Participants

9

Primary sponsor

Full Name

Canariabio Inc.

Organisation Type

Pharmaceutical company

Country Of Registered Address

Korea, Republic of

Contract research organisations

Name

Iqvia Rds Inc.

Responsibilities

Clinical supplies management, DSMB management/oversight, immune response assay

Name

Bioclinica Inc.

Third parties

• {"country":"United States","full_name":"Myriad Genetics Inc.","duties_or_roles":"BRCA testing","organisation_type":"Laboratory/Research/Testing facility"}
• {"country":"United States","full_name":"Iqvia Rds Inc.","duties_or_roles":"Clinical supplies management, DSMB management/oversight, immune response assay","organisation_type":"Pharmaceutical company"}
• {"country":"United States","full_name":"Quest Diagnostics Nichols Institute Inc.","duties_or_roles":"Genetic testing","organisation_type":"Laboratory/Research/Testing facility"}
• {"country":"United States","full_name":"Bioclinica Inc.","duties_or_roles":"","organisation_type":"Laboratory/Research/Testing facility"}